A Study of IMP4297 as Maintenance Treatment Following First-line Chemotherapy in Patients With Advanced Ovarian Cancer
Status:
Recruiting
Trial end date:
2022-12-30
Target enrollment:
Participant gender:
Summary
IMP4297 is a PARP inhibitor. This is a 2:1 randomized, double-blind, placebo-controlled study
conducted in patients with advanced (FIGO Stage III or IV) ovarian cancer to evaluate
Efficacy and Safety of IMP4297 for Maintenance Treatment